|
Advertisement | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Lipid Research, Vol. 44, 560-566, March 2003 Linoleic acid supplemention of Barth syndrome fibroblasts restores cardiolipin levels: implications for treatment
Academic Medical Center, University of Amsterdam, Laboratory Genetic Metabolic Diseases, Emma Children's Hospital and Department of Clinical Chemistry, PO Box 22700, 1100 DE Amsterdam, The Netherlands
1 To whom correspondence should be addressed. e-mail: r.j.wanders{at}amc.uva.nl The object of this study was to investigate whether the levels of cardiolipin in cultured skin fibroblasts of patients with Barth syndrome (BTHS) can be restored by addition of linoleic acid to growth media. To this end, fibroblasts from controls and BTHS patients were grown in the presence or absence of linoleic acid. High-performance liquid chromatography-electrospray ionization tandem mass spectrometry was used for quantitative and compositional analysis of cardiolipin. Incubation of cells from both BTHS and controls with different concentrations of linoleic acid led to a dose- and time-dependent increase of cardiolipin levels. The increased levels of cardiolipin in fibroblasts of BTHS patients after treatment with linoleic acid indicate that an increased amount of linoleic acid in the diet might be beneficial to BTHS patients.
Abbreviations: BTHS, Barth syndrome; CL, cardiolipin; IS, internal standard; PG, phosphatidylglycerol; TAZ, Tafazzin Supplementary key words cardiomyopathy Tafazzin mitochondrial myopathy HPLC-ESI-MS/MS cardiolipin linoleic acid
This article has been cited by other articles:
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Advertisement | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||